Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Name: Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.
License: Public Domain

Zhejiang Cancer Hospital

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

non-small-cell-lung-cancer

non-small cell lung cancer, pdl1 gene mutation

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 162488
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.